

## Engineering slow acting mono-Zn variants of metallo $\beta$ -lactamases as a crystallographic and spectroscopic platforms for drug discovery

Ben A. Shurina<sup>§</sup>, Jamie VanPelt<sup>§</sup>, Matthew Morris<sup>§</sup>, Jonathan Montgomery<sup>§</sup>, Matthew Orischak<sup>§</sup>, Robert Bonomo<sup>&</sup>, Jay Nix<sup>#</sup>, Richard C. Page<sup>§\*</sup>

<sup>§</sup>Department of Chemistry & Biochemistry, Miami University, Oxford, OH 45056 USA

<sup>&</sup>Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106 USA

<sup>#</sup>Molecular Biology Consortium, Beamline 4.2.2, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA

Corresponding Author: Richard C. Page, [pagerc@MiamiOH.edu](mailto:pagerc@MiamiOH.edu)

Antibiotic resistance is a persistent threat in the clinic. The widespread use of  $\beta$ -lactam containing antibiotics has put evolutionary pressure on bacteria to develop an extensive library of enzymes that degrade these compounds. This family of enzymes, known as  $\beta$ -lactamases, are pervasive, adaptive, and omnipresent. Of particular concern are the metallo- $\beta$ -lactamases such as New Delhi Metallo- $\beta$ -lactamase (NDM), and VIM-2, as they readily degrade many of our last-resort antibiotics. One strategy for overcoming the threat of  $\beta$ -lactamases is the development of  $\beta$ -lactamase inhibitors and co-administering them with  $\beta$ -lactam containing antibiotics, as inhibiting the  $\beta$ -lactamase should preserve the integrity of the antibiotic. Unfortunately, there are currently no FDA approved inhibitors for the NDM or VIM families of  $\beta$ -lactamases. While several members of these families of proteins have been successfully crystallized and structures have been deposited into the PDB, all of the structures to date have only successfully captured  $\beta$ -lactam containing compounds in a hydrolyzed state, as the rate of hydrolysis is much faster than the timescale required for crystallization. The Page lab has engineered slow acting mono-Zinc variants of NDM-4 and VIM-20 for use as a crystallographic and spectroscopic platform to probe the pre-hydrolyzed enzyme-substrate complex. A crystal structure of our mono-Zinc version of NDM-4, called NDM-X has been solved at 1.4Å resolution with minimal structural changes relative to native NDM-4. A 10,000X reduction in activity shows promise for future crystal soaking experiments.